Get started

Healthcarestocks

Whatever WORX Right?WORX stock tested a key FIb level on Wednesday being the 50 fib line after plotting the top anchor at the recent high the first time WORX busted above the 50 fib. Before this latest round of testing, the last time WORX reached this key level it was rejected heavily. A few weeks ago, the company announced that it had regained compliance with the NASDAQ listing requirements. At the same time, it announced that Tim Hannibal, current COO, would become the new CEO. He stated that “over the last 10-15 years, technology within the healthcare industry has evolved both in cost and complexity. Unfortunately, the technology which was implemented within different hospital departments and with disparate objectives has failed to provide the promised advancements.” As a leader in providing software to healthcare institutions, there is a clear benefit that Scworx could gain from the pandemic’s current state and the ending of Covid-19. With all of this in mind, is WORX stock worth keeping an eye on? Quote source and read more: 4 Epicenter Penny Stocks You Need to Know About in 2021
NASDAQ:WORX
by PennyStocks101
HDVY Technical AnalysisSomeone had asked me to chart this up two weeks ago if I recall and I'd set up a buy grid using Fibonacci, some trend lines and your basic Hi's / Low's and everything goes. I'll post the updated TA version in a bit here but we can see that at the very least, my stop market buy would have filled and a gain at the top of the Fib overlay I'd made at that time would have been met. So holy cow!! this beast popped hard. Not unusual for OTC stocks to pump like this and flash wick huge on the top side. I prefer consolidations, breakouts, gap fills and things like that so I personally would't do anything at the moment but possible wait for a cup & handle situation. Update posting in 3 . . 2 . .
OTC:HDVY
by FudBox
31
JD.com HEALTH ~ Looking for movement to appear soon... JD HEALTH as retail pharmacy has started to be online, and notice increase of sale retail is now online multiple supported showing JD Health have been ranging near the IPO price, premature Head and Shoulder is forming up. Currently it's at lower zone, expecting as break out happening soon with the lower range support to TP1 $124 and above.. If support break we might be looking under IPO prices. Circle indicate possible low. Good Luck!!
HKEX:6618Long
by JarvisTan
2
BFLY Should Hold SupportBFLY Current Price $12.75 Price Target $20 This company is a fairly valued (5x PE) innovative healthcare company. Butterfly Networks is cutting the cost of ultrasounds by 90% with their handheld device, the new ultrasound platform uses a semiconductor rather than a crystal based sound wave. They are targeting emerging markets with this amazing cost cutting innovation. It hasn’t been a better time to buy BFLY in quite some time as BFLY is now trading on crucial support around $12.50. I think we hold this support line and trade up to the top line of resistance around $15 within the next couple months then we should move up to $20 in the coming months.
NYSE:BFLYLong
by Value-Invest
1
BFLY Price Target $25BFLY Current Price $14.36 Price Target $20 $10c 10/15 ($470, 3% till breakeven) We have been in BFLY since $10. This company is a fairly valued (5x PE) innovative healthcare company. Butterfly Networks is cutting the cost of ultrasounds by 90% with their handheld device, the new ultrasound platform uses a semiconductor rather than a crystal based sound wave. They are targeting emerging markets with this amazing cost cutting innovation. We saw insiders buy over 2 million worth of shares earlier this month, which signifies confidence of the business within the company. This is a long term hold for me!
NYSE:BFLYLong
by Value-Invest
RGLS Showing Interesting LevelsRGLS continues pivoting around that 618 Fib line. Overall, it has held a clear uptrend despite the pullback. Trend line lines up almost perfectly with the latest higher lows put in. RNA companies remain a focus. In this case, it's not covid but kidney diseases. "In mid-May, Regulus Therapeutics announced an incremental update of its autosomal dominant polycystic kidney disease program. The CEO of the company, Jay Hagan said, “As previously reported, the ninth and final patient was trending well at the end of the dosing period and saw their polycystin levels continue to rise until study completion, twenty-eight days after the last dose. This pattern was generally consistent across the first cohort and further enhanced the overall mean changes from baseline for both biomarkers." PLUS upcoming presentation of RGLS4326 for the treatment of ADPKD at the PKD Connect Conference 2021 this Friday (6/25) could be something to keep in mind right now too. Quote Source: 7 Hot Penny Stocks to Watch That Are Trending Right Now
NASDAQ:RGLS
by PennyStocks101
$CLOV Clover Health Investments tries to recoverThe title recently had an explosive exploit touching really important levels, as a result of these unfortunately profit took prevail and the price of the title fell. Now it seems back the time of collection and the advisor Market Miracle that tries to identify the interests of big players in the market is providing us with an entry signal on the title $CLOV. The expected target is 17.25 USD but it could also be a starting point from which to take new leaps. Analyzing the title on the graph I expect to see a price action similar to the one I designed, Of course surprises are always possible especially on a low capitalization stock like $CLOV so pay attention and analyze well what for you is the possible price action to be able to current any necessary price mediation. This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
NASDAQ:CLOVLong
by MarketMiracleAdvisor
BFLY HITTING SUPPORT - $20 PRICE TARGETBFLY - Current Price $ 10.23 Price Target (short-term) $12.50 Long Term $20 This company created an Ultra sound that is hand held and can give you the same images and accuracy as the ones in use in the USA. The best part about the innovation is the cost reduction. These cost under 3k while most ultra sounds cost a million +. This innovative tech will be used to bring this technology to poorer developing countries. Just reported $0.57 EPS last quarter on an annual basis that would be a PE of 4.5x which is cheap given the growth prospects for this company. Looks great on the chart as we are seeing a double bottom off that $9.80 level. Long shares and calls here.
NYSE:BFLYLong
by Value-Invest
20-150% Profits Possible on SEEL Therapeutics My favorite new indie stock, Seelos Therapeutics, was recently upgraded from a price target of $4.70 to a whopping $15. For this to happen, it may have to beat some bears (in SPY) and sharks (in short interest). Short interest in the stock is down, with most shares not available to short. This is positive and bullish for shorter term. The stock market looks to continue its rally, with minor downs, as usual, until further notice. Biden's Infrastructure Plan may continue to stimulate the market to amazing new highs. I may invest in this on Monday. I really need to make some $$ for food, rent, and my beloved kitten. If it follows DLPN (Dolphin Entertainment), it may even beat its updated price target! DLPN was a rocket ship this year! Everyone go out and see some seals! News had it that the Great White Sharks of Cape Town have disappeared this year! Enough synchronicities, this is an ethical company that works on healing chronic diseases. Resources: stockinvest.us stocktwits.com finance.yahoo.com www.nasdaq.com seekingalpha.com investorshub.advfn.com seelostherapeutics.com #mayweallgetrichtogether
SLong
by Grandmaster76
THYROCARE recently turned trend, about to test resistance zone.Hi. In this 1D chart I've plotted a few things: the recent MA 56 crossing that marked a trend turn, the approaching resistance zone from November last year and an interpretation of the movements since then as Elliott Waves. You can also see: There is still rooms for the Williams 224 to climb further. The historical volatility is lower than it was in November indicating a more stable trend. The Ichimoku is agreeing with the recent trend turn. There is possibility that the MACD will turn down across its signal but I believe that it will either skirt the signal and then continue rising or pass below it momentarily as the current Elliott Correction Wave plays out. It should be noted that the fundamentals of THYROCARE are absolutely excellent and therefore could be worth holding not only for the immediate future. Thank you. Please if you have any thoughts or comments do leave them below and I would gladly discuss or adjust my interpretations and methods. This does not constitute financial advice. Any prices, even if explicitly stated, are presented with intent to discuss the symbol and potential interpretations. Any trades shown or mentioned are examples and neither recommendations or mandates.
NSE:THYROCARELong
by Kabeldon
HEPA - a good buy opportunity? Very likely for me!First of all, I am not an expert when it comes to pharmaceutical companies! Why did I pick Hepion Pharmaceuticals (@hepionpharma)? 1. From a business perspective, they are healthy (Quick Ration of Assets vs. Liabilities is 9 to 1) 2. They came from a super high share price and are currently on a super low level 3. They are working on a product CRV431 (recently completed Phase 1 of 3) to tackle chronic liver disease and so far the results seem promising: Half a billion people worldwide are at risk unless new therapies are found. CRV431 is Hepion’s clinical phase, lead oral drug candidate for nonalcoholic steatohepatitis (NASH) and viral hepatitis-induced liver disease. CRV431 meets all of Hepion’s criteria for an effective and unique pleiotropic liver disease drug. Currently Phase 1 consists of three parts and the collective data from the Parts 1 and 2 demonstrate a favorable pharmacological, pharmacokinetic, and safety profile for CRV431. Part 3 data results are expected and with Phase 2 we might see bigger interest. Take a look at the chart and the health of the company with future prospective - then shape your own opinion. - This is no financial advice, so trade with care!- For transparency reasons: I am invested in $HEPA with 2/10 of my stock account size.
NASDAQ:HEPALong
by RedFoxTrading
MDT price target raised to 133; pent-up demand provides tailwindMDT price target was just upgraded to $133 by Citi. I see it overshooting that in the long run. Elective surgeries have been put off and doctor visits have been down throughout the pandemic so the amount of pent-up demand for surgical/medical care is going to be through the roof. With an aging population, healthcare is a MUST as a sector to allocate to. MDT is an excellent way to play this sector. After periods of consolidation, MDT looks ready to head towards it's price target. My guess is it hits $150 before it reaches any significant resistance. In terms of fundamentals, their current ratio is 2.1020, meaning they could pay their current liabilities 2 times over if sh*t hit the fan and business came to a complete halt. Highly unlikely, but if it did happen, you would be sheltered for a period of time.
NYSE:MDTLong
by EBITDAtiger
2
$SSY Announces $2 Million ExpansionSunlink Health Systems, Inc. Announces $2 Million Expansion, Capital and Operating Improvements at Trace Regional Hospital announced today that its wholly-owned subsidiary, Trace Regional Hospital, has implemented its Trace Forward Capital Plan totaling approximately $2 million to expand, upgrade and improve its physical plant, patient care, ancillary services and support areas. The Trace Forward Capital Plan includes an 8-bed expansion of its Pathways Care Program, a geriatric behavioral health service, which will bring Pathways to 26 total beds. "The expansion and upgrade of our Pathways Care Program will allow us to meet the growing demand for quality senior behavioral services as well as acute care hospital services in our northeast Mississippi service area." We wish to thank our elected Mississippi and Federal officials and staff for making these investments possible under various provisions of the CARES Act, which are funding a portion of the Trace Forward Capital Plan, and for prioritizing quality and access to care for the citizens of the Houston and Chickasaw County area during this uncertain and potentially disastrous period of the COVID-19 pandemic." finance.yahoo.com
AMEX:SSY
by AlenCiken
$CHEK Receives FDA IDE Approval for Pivotal Study of C-Scan®Check-Cap Receives FDA IDE Approval for Pivotal Study of C-Scan® today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational Device Exemption (IDE) application, permitting Check-Cap to begin a pivotal study of C-Scan in the U.S. The pivotal study will evaluate safety and performance of C-Scan as well as subject compliance with C-Scan. Now with IDE in hand, we aim to enter the last phase of demonstrating the clinical potential of C-Scan in the U.S., with the ultimate goal of commercialization in this important market. "We are in active discussions with a number of clinical sites as part of our preparations to begin the pivotal study in late 2021. finance.yahoo.com
NASDAQ:CHEK
by AlenCiken